Skip to main content
. 2023 Jul 25;24(15):11887. doi: 10.3390/ijms241511887

Table 8.

Imaging biomarkers for ICIs response in NSCLC, evaluated by PET-CT.

Biomarker Key Finding
tMTV (18F-FDG PET_CT) tMTV ≥ 75cm3 can indicate unfavorable outcomes in aNSCLC treated with pembrolizumab [144].
89Zr-atezolizumab Higher pre-treatment signal of 89Zr-atezolizumab in atezolizumab responders [143].
89Zr-durvalumab Higher pre-treatment signal of 89Zr-durvalumab in durvalumab responders [146].

tMTV—metabolic tumor volume; 18F-FDG—18F-fluorodeoxyglucose; PET-CT—positron emission tomography-computed tomography; aNSCLC—advanced non-small cell lung cancer.